Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 27

recruiting
3 987
countries
28
conditions
2 109

726 trials match your criteria

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide

Sjogren's syndrome

Not recruiting

A Study Testing Imeroprubart for Adults with Primary Sjogren's Disease with Moderate to Severe Symptoms

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart

Dermatitis atopic

Not recruiting

A study testing BFB759 compared to placebo to evaluate effectiveness and safety in adult patients with atopic dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BFB759

Type 2 diabetes mellitus+2

Not recruiting

A Study of Cagrilintide and Semaglutide for Weight Loss in People with Type 2 Diabetes and Overweight or Obesity

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide

Study of navenibart to prevent attacks in adults and adolescents with Hereditary Angioedema

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Navenibart

Migraine

Not recruiting

Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins

Migraine

Not recruiting

Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins

Psoriasis

Not recruiting

Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast

Psoriasis

Not recruiting

Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast

Study of Verekitug to improve symptoms in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.